<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Imaging</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>FDA clears 11 Aidoc AI triage indications</title>
      <description>
        <![CDATA[Aidoc Medical Ltd.'s Care AI foundation model secured 11 new U.S. FDA-cleared indications for use in emergency department triage. Now, with 14 total cleared indications enabling comprehensive evaluation and prioritization of abdomen CTs in a single workflow, Aidoc Care can help health systems identify critical findings more quickly and mitigate delays caused by overcrowding and imaging backlogs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728066</guid>
      <pubDate>Wed, 21 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728066-fda-clears-11-aidoc-ai-triage-indications</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-digital-health.webp?t=1683125967" type="image/jpeg" medium="image" fileSize="229937">
        <media:title type="plain">Artificial intelligence and digital health icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Crescom wins FDA clearance for bone analysis</title>
      <description>
        <![CDATA[Crescom Co. Ltd., an AI musculoskeletal imaging company, gained U.S. FDA 510(k) clearance Dec. 24 for MediAI-BA, its AI-powered pediatric and adolescent bone age analysis software.
Classified as a class II medical device, MediAI-BA evaluates bone age and suggests predicted adult height based on growth plate status assessed by hand and wrist X-ray imaging. Prior clinical trial results demonstrated MediAI-BA had specialist-level accuracy, recording a mean absolute deviation (MAD) of 0.39 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727223</guid>
      <pubDate>Wed, 24 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727223-crescom-wins-fda-clearance-for-bone-analysis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Crescom-MediAI-BA-24dec25.webp?t=1766601685" type="image/jpeg" medium="image" fileSize="71686">
        <media:title type="plain">Crescom MediAI-BA</media:title>
        <media:description type="plain">Crescom MediAI-BA bone age analysis software. Credit: Crescom</media:description>
      </media:content>
    </item>
    <item>
      <title>Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints</title>
      <description>
        <![CDATA[Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to interim results. To date, 11 of the 12 patients treated with RAD-101 (F18-Pivalate) achieved concordance with MRI (the primary endpoint) as assessed by PET imaging of brain metastases. The results showed significant and selective tumor uptake, and images confirm metabolic activity in brain metastases compared to equivocal MRI findings.
]]>
      </description>
      <guid>http://www.bioworld.com/articles/727073</guid>
      <pubDate>Tue, 16 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727073-radiopharm-theranostics-rad-101-meets-brain-metastases-endpoints</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/PET-scan.webp?t=1619184556" type="image/png" medium="image" fileSize="296278">
        <media:title type="plain">PET imaging</media:title>
        <media:description type="plain">PET imaging. Credit: Miroslaw Janowski</media:description>
      </media:content>
    </item>
    <item>
      <title>Brainomix 360 Stroke increases endovascular thrombectomy rates</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Brainomix Ltd. reported the publication of a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment, a minimally invasive surgical procedure for patients with large vessel occlusion stroke, and reduced delays in patient triage and transfer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726454</guid>
      <pubDate>Wed, 03 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726454-brainomix-360-stroke-increases-endovascular-thrombectomy-rates</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Brainomix-360-E-aspects-software-3-20.webp?t=1742505795" type="image/jpeg" medium="image" fileSize="555642">
        <media:title type="plain">Brainomix 360 Stroke platform</media:title>
        <media:description type="plain">Brainomix 360 Stroke platform. Credit: Brainomix Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>GE Healthcare expands imaging line with $2.3B Intelerad buy</title>
      <description>
        <![CDATA[GE Healthcare Technologies Inc. agreed to purchase medical imaging company Intelerad Medical Systems Inc. for $2.3 billion in cash, boosting its capabilities in cardiology and radiology. The deal, expected to close in the first half of 2026, advances GE Healthcare's dual strategies of expanding from primarily inpatient products to outpatient and ambulatory care settings and tripling its cloud-enabled products by 2028.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726231</guid>
      <pubDate>Fri, 21 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726231-ge-healthcare-expands-imaging-line-with-23b-intelerad-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/MA-missing-puzzle-pieces.webp?t=1714684952" type="image/jpeg" medium="image" fileSize="265913">
        <media:title type="plain">M&amp;A letters over missing puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Hologic to go private in $18.3B deal</title>
      <description>
        <![CDATA[In the largest med-tech M&A deal in nearly three years, Hologic Inc. agreed to be acquired by funds led by Blackstone and TPG in a transaction valued at $18.3 billion. After five months of rumored negotiations, the outlined deal provides Hologic shareholders with $76 per share in cash plus up to $3 per share in contingent value rights (CVR) to be paid on achievement of revenue goals for the breast health business over the next two years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725145</guid>
      <pubDate>Tue, 21 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725145-hologic-to-go-private-in-183b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Glass-globe-with-documents-and-pen.webp?t=1759956850" type="image/jpeg" medium="image" fileSize="456537">
        <media:title type="plain">Glass globe with documents and pen</media:title>
      </media:content>
    </item>
    <item>
      <title>Ultromics raises $55M for AI platform to tackle heart failure</title>
      <description>
        <![CDATA[Ultromics Ltd. raised $55 million in a series C financing round to expand its commercial footprint across the U.S. and invest in the development of new AI modules for earlier, more accurate detection of cardiovascular disease, Ross Upton, CEO and founder of Ultromics told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722561</guid>
      <pubDate>Thu, 31 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722561-ultromics-raises-55m-for-ai-platform-to-tackle-heart-failure</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>AI-based video biomarker developed for aortic stenosis</title>
      <description>
        <![CDATA[Researchers from the Yale University filed for protection of a multi-modal approach to predict the progression risk of a heart condition using artificial intelligence algorithms applied to cardiovascular videos.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722549</guid>
      <pubDate>Wed, 30 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722549-ai-based-video-biomarker-developed-for-aortic-stenosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/aortic-stenosis-video-30july25.webp?t=1753914120" type="image/jpeg" medium="image" fileSize="217684">
        <media:title type="plain">Aortic stenosis video</media:title>
        <media:description type="plain">WO2025151635-A1, “A multi-modal video-based progression score for aortic stenosis using artificial intelligence.”Assignee: Yale UniversityInventors: Khera, Rohan; Oikonomou, EvangelosIPC codes: G16H 30/40; G16H 30/20; A61B 8/08; G06T 7/00Publication date: July 27, 2025Earliest priority details: US2024619241, Jan. 9, 2024</media:description>
      </media:content>
    </item>
    <item>
      <title>Lunit, Microsoft to codevelop cloud-based clinical AI solutions</title>
      <description>
        <![CDATA[Lunit Inc. reported a new collaboration with Microsoft Corp. July 2 to jointly develop medical AI programs accessible on Microsoft’s Azure cloud platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721647</guid>
      <pubDate>Thu, 03 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721647-lunit-microsoft-to-codevelop-cloud-based-clinical-ai-solutions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Lunit-10apr25.webp?t=1751573138" type="image/jpeg" medium="image" fileSize="492132">
        <media:title type="plain">Lunit</media:title>
      </media:content>
    </item>
    <item>
      <title>Deski raises $6M for Heartfocus cardiac imaging software</title>
      <description>
        <![CDATA[Deski SAS raised $6 million in a seed round to support the launch of its cardiac imaging software, Heartfocus, in the U.S. The AI-driven heart exam tool helps health care professionals perform echocardiograms from any ultrasound probe to enable the early detection of heart disease. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721151</guid>
      <pubDate>Fri, 20 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721151-deski-raises-6m-for-heartfocus-cardiac-imaging-software</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Deski-HeartFocus-20jun25.webp?t=1750451570" type="image/jpeg" medium="image" fileSize="201599">
        <media:title type="plain">Deski Heart Focus</media:title>
      </media:content>
    </item>
    <item>
      <title>Device for monitoring wounds without removing dressings</title>
      <description>
        <![CDATA[Researchers from the University at Buffalo, the State University of New York (SUNY), filed for protection of their development of a new imaging technology that uses radar and AI to see through dressings to monitor wounds and other skin conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721129</guid>
      <pubDate>Wed, 18 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721129-device-for-monitoring-wounds-without-removing-dressings</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/wound-monitoring-18jun25.webp?t=1750279614" type="image/jpeg" medium="image" fileSize="307849">
        <media:title type="plain">Wound Monitoring</media:title>
        <media:description type="plain">WO2025117987-A1, “System and method for non-contact epidermal sensing.”Assignee: The Research Foundation for The State University of New YorkInventors: Xu, Wenyao; Xia, Jun; Zhang, XiaoyuIPC codes: A61B 5/00; G06T 7/00; G06T 7/62; A61B 5/0507Publication date: June 5, 2025Earliest priority details: US2023604890, Nov. 30, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Seeme helps measure, detect consciousness after TBI</title>
      <description>
        <![CDATA[In what represents their first patenting, researchers from New York’s Stony Brook University filed for protection for development of a system and method that uses computer vision to analyze microscale facial movements in order to objectively help diagnose, monitor, and treat disorders of consciousness.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720276</guid>
      <pubDate>Fri, 23 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720276-seeme-helps-measure-detect-consciousness-after-tbi</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/SeeMe-23may25.webp?t=1748035700" type="image/png" medium="image" fileSize="117824">
        <media:title type="plain">SeeMe</media:title>
        <media:description type="plain">WO2025101473-A1, “System and method to objectively detect recovery of human consciousness.”Assignee: The Research Foundation for The State University of New YorkInventors: Mofakham, Sima; Mikell, Charles; Cheng, XiIPC codes: G06V 20/40; H04N 19/167; A61B 5/16; A61B 5/11; G06T 7/20Publication date: May 15, 2025Earliest priority details: US2023596376, Nov. 6, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Rebrain’s brain targeting AI secures MDR CE mark</title>
      <description>
        <![CDATA[<a href="https://www.cortellis.com/intelligence/qsearch/%22rebrain%20sas%22%20?indexBased=true&searchCategory=ALL">Rebrain SAS</a>'s Optimmri platform received European Medical Device Regulation CE mark certification to enable surgeons to identify areas of interest in the brain during deep brain stimulation procedures for Parkinson's disease and essential tremor. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/719947</guid>
      <pubDate>Fri, 16 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719947-rebrains-brain-targeting-ai-secures-mdr-ce-mark</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Focal-seizure-illustration.webp?t=1747174585" type="image/jpeg" medium="image" fileSize="146135">
        <media:title type="plain">Illustration of brain and brain waves, concept of focal seizure</media:title>
      </media:content>
    </item>
    <item>
      <title>​Chipiron building ultra-low portable MRI scanner following $17M raise</title>
      <description>
        <![CDATA[Chipiron SA will produce a prototype of its ultra-low portable magnetic resonance imaging (MRI) scanner, after raising $17 million in series A financing, as it looks to make MRI more accessible.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719906</guid>
      <pubDate>Mon, 12 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719906-chipiron-building-ultra-low-portable-mri-scanner-following-17m-raise</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Chipiron-prototype-MRI-12may25.webp?t=1747088405" type="image/jpeg" medium="image" fileSize="336644">
        <media:title type="plain">Chipiron prototype MRI</media:title>
        <media:description type="plain">Chipiron prototype MRI. Credit: Chipiron</media:description>
      </media:content>
    </item>
    <item>
      <title>Radnet doubles down on breast cancer with $103M Icad buy</title>
      <description>
        <![CDATA[Radnet Inc. expanded its commitment to the use of AI in improving diagnosis of breast cancer with an all-stock purchase of Icad Inc. for approximately $103 million. The transaction is expected to close in the second or third quarter of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719143</guid>
      <pubDate>Wed, 16 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719143-radnet-doubles-down-on-breast-cancer-with-103m-icad-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Radiopharmaceuticals stake more territory in breast cancer care</title>
      <description>
        <![CDATA[Radiopharmaceuticals, including 16α-18F-fluoro-17β-estradiol (18F-FES) PET/CT, are emerging as powerful tools with new diagnostic and therapeutic potential in breast cancer diagnosis and treatment, Han Sang-won, professor from the department of nuclear medicine at Asan Medical Center, recently told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719079</guid>
      <pubDate>Tue, 08 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719079-radiopharmaceuticals-stake-more-territory-in-breast-cancer-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Radiopharma-AMC-4apr25.webp?t=1743796698" type="image/jpeg" medium="image" fileSize="331090">
        <media:title type="plain">Radiopharma AMC</media:title>
        <media:description type="plain">Han Sang-won of Asan Medical Center performing an 18F-FES PET scan in the diagnosis of potential metastatic breast cancer in Seoul, South Korea. Credit: Asan Medical Center</media:description>
      </media:content>
    </item>
    <item>
      <title>Plaque levels on AI-enhanced CCT impart greater relative risk for women</title>
      <description>
        <![CDATA[Women have substantially greater relative risk of major adverse cardiovascular events associated with a variety of plaque measures assessed by Cleerly Inc.’s AI-enhanced quantitative coronary computed tomography than men, an post hoc analysis of the CONFIRM2 trial found.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718874</guid>
      <pubDate>Mon, 07 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718874-plaque-levels-on-ai-enhanced-cct-impart-greater-relative-risk-for-women</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-scientific-overlay.webp?t=1729781889" type="image/jpeg" medium="image" fileSize="394419">
        <media:title type="plain">Heart scientific overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Samantree secures series B extension to take total to $20M</title>
      <description>
        <![CDATA[French venture capital firm Karista led a series B extension financing round for Samantree Medical SA to take the total raised in the round to $20 million. The funds will be used to launch Samantree’s Histolog scanner in the U.S. market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718666</guid>
      <pubDate>Fri, 04 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718666-samantree-secures-series-b-extension-to-take-total-to-20m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Black-dollar-sign-on-ombre-blue-background.webp?t=1738966542" type="image/jpeg" medium="image" fileSize="244111">
        <media:title type="plain">Black dollar sign on ombre blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Radiopharmaceuticals stake more territory in breast cancer care</title>
      <description>
        <![CDATA[Radiopharmaceuticals, including 16α-18F-fluoro-17β-estradiol (18F-FES) PET/CT, are emerging as powerful tools with new diagnostic and therapeutic potential in breast cancer diagnosis and treatment, Han Sang-won, professor from the department of nuclear medicine at Asan Medical Center, recently told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718665</guid>
      <pubDate>Fri, 04 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718665-radiopharmaceuticals-stake-more-territory-in-breast-cancer-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Radiopharma-AMC-4apr25.webp?t=1743796698" type="image/jpeg" medium="image" fileSize="331090">
        <media:title type="plain">Radiopharma AMC</media:title>
        <media:description type="plain">Han Sang-won of Asan Medical Center performing an 18F-FES PET scan in the diagnosis of potential metastatic breast cancer in Seoul, South Korea. Credit: Asan Medical Center</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Gleamer, Azmed AI-powered tools for chest X-rays</title>
      <description>
        <![CDATA[Two French startups, Gleamer SAS and Azmed SAS, received clearance from the U.S. FDA  for their AI-powered tools for chest X-rays. They join an increasing number of companies developing software tools to help clinicians detect a range of abnormalities on images, enhancing diagnostic accuracy, reducing delays and improving patient outcomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718634</guid>
      <pubDate>Tue, 01 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718634-fda-clears-gleamer-azmed-ai-powered-tools-for-chest-x-rays</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Lung-cancer-dna.webp?t=1681399693" type="image/png" medium="image" fileSize="1280944">
        <media:title type="plain">Illustration of lung cancer, DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>Have kit, will travel further: Telix PET-imaging agent approved by FDA</title>
      <description>
        <![CDATA[The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away from large hospitals. The FDA’s nod for the imaging agent, TLX007-CDx, now branded as Gozellix, has a long shelf life and needs less equipment and preparation compared to some other agents.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718612</guid>
      <pubDate>Tue, 25 Mar 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718612-have-kit-will-travel-further-telix-pet-imaging-agent-approved-by-fda</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-approved-icons-and-medical-professional.webp?t=1639686678" type="image/png" medium="image" fileSize="358484">
        <media:title type="plain">FDA approved icons and medical professional</media:title>
      </media:content>
    </item>
    <item>
      <title>Fibrosight launches in US for AI-based, stain-free MASH imaging</title>
      <description>
        <![CDATA[Histoindex Pte Ltd. launched its laboratory-developed test for metabolic dysfunction-associated steatohepatitis (MASH), Fibrosight, in the U.S. as the company’s first in a suite of next-generation digital pathology solutions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718005</guid>
      <pubDate>Fri, 21 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718005-fibrosight-launches-in-us-for-ai-based-stain-free-mash-imaging</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/FibroSIGHT-3-20.webp?t=1742593581" type="image/jpeg" medium="image" fileSize="392316">
        <media:title type="plain">Fibrosight imaging by Histoindex</media:title>
        <media:description type="plain">Fibrosight stain-free MASH imaging. Credit: Histoindex Pte Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Have kit, will travel further: Telix PET-imaging agent approved by FDA</title>
      <description>
        <![CDATA[The U.S. FDA’s approval of Telix Pharmaceuticals Ltd.’s kit for preparing prostate-specific membrane antigen-PET imaging for prostate cancer widens the opportunities for patients who live far away from large hospitals. The FDA’s nod for the imaging agent, TLX007-CDx, now branded as Gozellix, has a long shelf life and needs less equipment and preparation compared to some other agents.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718516</guid>
      <pubDate>Fri, 21 Mar 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718516-have-kit-will-travel-further-telix-pet-imaging-agent-approved-by-fda</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-approved-icons-and-medical-professional.webp?t=1639686678" type="image/png" medium="image" fileSize="358484">
        <media:title type="plain">FDA approved icons and medical professional</media:title>
      </media:content>
    </item>
    <item>
      <title>Samsung life science fund invests $10M in C2N Diagnostics</title>
      <description>
        <![CDATA[Samsung Life Science Fund made its first strategic investment of the year into C2N Diagnostics LLC, underscoring the rising potential of blood-based diagnostics in detecting and monitoring the risk of Alzheimer’s disease for the masses.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717923</guid>
      <pubDate>Fri, 14 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/717923-samsung-life-science-fund-invests-10m-in-c2n-diagnostics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign.webp?t=1592343941" type="image/png" medium="image" fileSize="265558">
        <media:title type="plain">Gold dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA draft for OI contrast agents allows intrasubject comparators</title>
      <description>
        <![CDATA[The U.S. FDA drafted a guidance for clinical trials for evaluation of optical imaging (OI) agents. The policy may allow clinical studies to evaluate an OI agent by means of an intrasubject study design, which would save time and money for the sponsor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717721</guid>
      <pubDate>Wed, 05 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717721-fda-draft-for-oi-contrast-agents-allows-intrasubject-comparators</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-icons-and-doctor.webp?t=1666903713" type="image/png" medium="image" fileSize="238204">
        <media:title type="plain">FDA icons and doctor</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA accepts Telix BLA for kidney cancer imaging agent</title>
      <description>
        <![CDATA[After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for its kidney cancer PET imaging agent, TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), granting it a priority review with a PDUFA date of Aug. 27, 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718017</guid>
      <pubDate>Tue, 04 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/718017-fda-accepts-telix-bla-for-kidney-cancer-imaging-agent</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-cancer-tumor.webp?t=1745263246" type="image/jpeg" medium="image" fileSize="344153">
        <media:title type="plain">Illustration of tumor on kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>Philips lands EU MDR for radiology remote scanning</title>
      <description>
        <![CDATA[Royal Philips NV recently secured EU MDR certification for the remote scanning capabilities on its Radiology Operations Command Center Console. The solution allows radiologists to remotely assist technologists in real-time by controlling scans to acquire images needed for improved diagnostic confidence and patient outcomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717632</guid>
      <pubDate>Fri, 28 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717632-philips-lands-eu-mdr-for-radiology-remote-scanning</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/Radiology-Operations-Command-Center-28feb25.webp?t=1740781443" type="image/jpeg" medium="image" fileSize="341728">
        <media:title type="plain">Royal Philips NV Radiology Operations Command Center</media:title>
        <media:description type="plain">Royal Philips NV Radiology Operations Command Center. Credit: Royal Philips NV</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA accepts Telix BLA for kidney cancer imaging agent</title>
      <description>
        <![CDATA[After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for its kidney cancer PET imaging agent, TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), granting it a priority review with a PDUFA date of Aug. 27, 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717823</guid>
      <pubDate>Thu, 27 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717823-fda-accepts-telix-bla-for-kidney-cancer-imaging-agent</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-cancer-tumor.webp?t=1745263246" type="image/jpeg" medium="image" fileSize="344153">
        <media:title type="plain">Illustration of tumor on kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA accepts Telix BLA for kidney cancer imaging agent</title>
      <description>
        <![CDATA[After a second round, the U.S. FDA has accepted for review radiopharmaceutical company Telix Pharmaceuticals Ltd.’s BLA for its kidney cancer PET imaging agent, TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), granting it a priority review with a PDUFA date of Aug. 27, 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717611</guid>
      <pubDate>Wed, 26 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717611-fda-accepts-telix-bla-for-kidney-cancer-imaging-agent</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-cancer-tumor.webp?t=1745263246" type="image/jpeg" medium="image" fileSize="344153">
        <media:title type="plain">Illustration of tumor on kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>Scientists develop scanner to see undetectable breast tumors​</title>
      <description>
        <![CDATA[Scientists at the University of Aberdeen developed a new scanner that distinguishes breast tumor material from healthy tissue more accurately than current magnetic resonance imaging (MRI) methods.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717610</guid>
      <pubDate>Wed, 26 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717610-scientists-develop-scanner-to-see-undetectable-breast-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
  </channel>
</rss>
